| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11007689 | Lung Cancer | 2018 | 12 Pages |
Abstract
To our knowledge, this is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC. The economic burden was substantial in all three countries. Treatment of NSCLC is associated with large annual national costs, mainly incurred during disease progression.
Keywords
SASQOLQuality of lifeMRIstandard deviationEconomic burdenemergency departmentMagnetic resonance imagingcomputed tomographyPositron emission tomographyAdjuvant therapyNon-small cell lung cancer (NSCLC)NSCLCNon-small cell lung cancerconfidence intervalStatistical Analysis SoftwareIndirect costdirect costUnited KingdomPET
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stefan Andreas, Christos Chouaid, Sarah Danson, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Mark Price,